BioLife Solutions climbs on $1.5 billion Repligen buyout

Repligen

22/07/2026 11:31

** Shares of cell and gene therapy tools maker BioLife Solutions BLFS.O rise 2.7% to $29.99 premarket
** Life sciences company Repligen RGEN.O says it will buy BioLife in a deal valued at about $1.5 billion 
** RGEN says the deal value comprises of 64% in Repligen common stock and 36% in cash
** BioLife stockholders will receive $11.25 per share in cash and 0.1442 shares of Repligen common stock, which equates to a total value of $31.00 per share — a premium of about 6.2% to BioLife's last close
** The deal is expected to close in the fourth quarter of 2026
** Up to last close, stock up 20.7% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))